Cargando…

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Detalles Bibliográficos
Autores principales:	Aldred, Jason, Freire-Alvarez, Eric, Amelin, Alexander V., Antonini, Angelo, Bergmans, Bruno, Bergquist, Filip, Bouchard, Manon, Budur, Kumar, Carroll, Camille, Chaudhuri, K. Ray, Criswell, Susan R., Danielsen, Erik H., Gandor, Florin, Jia, Jia, Kimber, Thomas E., Mochizuki, Hideki, Robieson, Weining Z., Spiegel, Amy M., Standaert, David G., Talapala, Saritha, Facheris, Maurizio F., Fung, Victor S. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630263/ https://www.ncbi.nlm.nih.gov/pubmed/37817017 http://dx.doi.org/10.1007/s40120-023-00554-w

Ejemplares similares

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
por: Aldred, Jason, et al.
Publicado: (2023)

Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease
por: Rosebraugh, Matthew, et al.
Publicado: (2021)

Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion
por: Rosebraugh, Matthew, et al.
Publicado: (2021)

Stabile Levodopa-Spiegel durch subkutane Infusion von Foslevodopa/Foscarbidopa
por: Ebersbach, Georg
Publicado: (2021)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2021)

Modified reference based imputation and tipping point analysis in the presence of missing data due to COVID-19
por: Jin, Man, et al.
Publicado: (2021)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
por: Murata, Miho, et al.
Publicado: (2018)

Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
por: Chung, Sun Ju, et al.
Publicado: (2022)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Suicidality and divalproex sodium: analysis of controlled studies in multiple indications
por: Redden, Laura, et al.
Publicado: (2011)

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia
por: Gault, Laura M., et al.
Publicado: (2015)

Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease
por: Fernandez, Hubert H, et al.
Publicado: (2016)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
por: Chaudhuri, K. Ray, et al.
Publicado: (2023)

A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies
por: Boyd, James T., et al.
Publicado: (2019)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

First Gradually, Then Suddenly: Understanding the Impact of Image Compression on Object Detection Using Deep Learning
por: Gandor, Tomasz, et al.
Publicado: (2022)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
por: Burack, Michelle, et al.
Publicado: (2018)

Niobium-coated copper cavities for future accelerators
por: Amelin, Kirill
Publicado: (2017)

Physics and algorithms of the hadronic Monte-Carlo event generators: notes for a developer
por: Amelin, N S
Publicado: (1999)

Study of Nb-Cu 1.3 GHz SRF cavity resonators for future particle accelerators
por: Amelin, Kirill
Publicado: (2017)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Odin, Per, et al.
Publicado: (2018)

Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2017)

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
por: Waring, Jeffrey F., et al.
Publicado: (2015)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results
por: Fernandez, Hubert H, et al.
Publicado: (2015)

Real-Time Rain Rate Evaluation via Satellite Downlink Signal Attenuation Measurement
por: Giannetti, Filippo, et al.
Publicado: (2017)

Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
por: Kovács, Norbert, et al.
Publicado: (2022)

Bose-Einstein correlations and classical transport models
por: Amelin, N S, et al.
Publicado: (1995)

Acounting for multiparticle Bose-Einstein correlations in classical transport models
por: Amelin, N S, et al.
Publicado: (1995)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease
por: Epstein, Michael, et al.
Publicado: (2016)

Association between Selected Polymorphisms rs12086634, rs846910, rs4844880, rs3753519 of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD11B1) and the Presence of Insulin Resistance in the Polish Population of People Living in Upper Silesia
por: Szweda-Gandor, Nikola, et al.
Publicado: (2021)

Two Single Nucleotide Polymorphisms in the Von Hippel-Lindau Tumor Suppressor Gene in Patients with Clear Cell Renal Cell Carcinoma
por: Chrabańska, Magdalena, et al.
Publicado: (2023)

An object-oriented framework for the hadronic Monte-Carlo event generators
por: Amelin, N S, et al.
Publicado: (2000)

9th International Conference on Hadron Spectroscopy
por: Amelin, D, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_vhqnrjep9bjkalivujssqmpkj0